Gallen International Expert Consensus Conference showed that NACT had been extensively used in patients with human epidermal growth factor receptor 2 positive (HER2+) and triple-negative (TN) breast cancer, especially those with axillary lymph node metastasis, to improve survivals (Curigliano et al., 2019). Here, ERBB2 is linked to breast cancer.